Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study. // The Lancet Gastroenterology & Hepatology. – URL: https://www.sciencedirect.com/science/article/pii/S2468125326002633?dgcid=rss_sd_all
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study. The Lancet Gastroenterology & Hepatology. https://www.sciencedirect.com/science/article/pii/S2468125326002633?dgcid=rss_sd_all
“Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study.” The Lancet Gastroenterology & Hepatology.
@article{article68522,
title = {Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study},
journal = {The Lancet Gastroenterology \& Hepatology},
url = {https://www.sciencedirect.com/science/article/pii/S2468125326002633?dgcid=rss_sd_all}
}